Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised Double-blind (Sponsor Open), Placebo Controlled, Single Ascending Dose, First Time in Human Study in Participants With Mild to Moderate Asthma to Assess Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3511294 Administered Subcutaneously

Trial Profile

A Randomised Double-blind (Sponsor Open), Placebo Controlled, Single Ascending Dose, First Time in Human Study in Participants With Mild to Moderate Asthma to Assess Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3511294 Administered Subcutaneously

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs GSK-3511294 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; First in man
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Oct 2018 Planned number of patients changed from 72 to 48.
    • 31 Aug 2018 Biomarkers information updated
    • 15 Feb 2018 Planned primary completion date changed from 6 Dec 2018 to 24 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top